Burn Unspecified Degree, Deep Sedation
Conditions
Keywords
Burn patient, Depression, Ketamine, Suicidal tendencies
Brief summary
Adequate and effective pain management and prevention of depression are essential in burn patients. This study aims to investigate the effects of ketamine sedation in burn patients in terms of mood disorders, depression, anxiety, and suicidal tendency during intensive care follow-up in the postoperative period.
Detailed description
Aim: Adequate and effective pain management and prevention of depression are essential in burn patients. This study aims to investigate the effects of ketamine sedation in burn patients in terms of mood disorders, depression, anxiety, and suicidal tendency during intensive care follow-up in the postoperative period. Methods: The study was conducted with 67 patients between 18 and 65 years of age, who were ASA I-II class, had basic communication skills, no previous diagnosis of psychiatric illness, and no history of neuropsychiatric or cognitive disease or related treatment. After preoxygenation, anesthesia induction was performed with 2 mg/kg IV propofol and 1 mcg/kg IV fentanyl in the general anesthesia group. Anesthesia was continued with a mixture of 0.3-0.5 mcg/kg/min remifentanil, 2% sevoflurane, 50% air, 50% oxygen. In the sedation group, 1 mcg/kg IV fentanyl and 1 mg/kg IV ketamine were administered at induction; anesthesia was maintained by adding 30-50 mg IV propofol if necessary. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by the psychiatrist.
Interventions
None listed
Sponsors
T.C. Sağlık Bakanlığı Ankara Bilkent Şehir Hastanesi
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Who were ASA I-II class, * Had basic communication skills, * No previous diagnosis of psychiatric illness, * No history of neuropsychiatric or cognitive disease or related treatment.
Exclusion criteria
* With a previous diagnosis of psychiatric illness, * Neuropsychiatric or cognitive illness, * Or a history of related treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Montgomery-Asberg Depression Rating Scale (MADRS), | 72 hours | In order to determine whether there is negative mood and depression; Montgomery-Asberg Depression Rating Scale (MADRS) was administered by the psychiatrist . |
| Hamilton Anxiety Rating Scale (HAM-A) | 72 hours | For anxiety; Hamilton Anxiety Rating Scale (HAM-A) was administered by the psychiatrist . |
| Beck Suicidal Ideation Scale (BSSI) | 72 hours | To determine whether there is suicidal ideation; Beck Suicidal Ideation Scale (BSSI) was administered by the psychiatrist . |
Countries
Turkey (Türkiye)
Outcome results
None listed